Can a radical transformation of preventive care reduce mortality by 20% in low SES populations? Preparatory work focusing on AUD/heavy alcohol use, HIV risk, and cardiovascular risk
Project Number5R34AA030484-03
Contact PI/Project LeaderBRAITHWAITE, RONALD SCOTT
Awardee OrganizationNEW YORK UNIVERSITY SCHOOL OF MEDICINE
Description
Abstract Text
Socioeconomic status (SES)-related health disparities are worsening substantially in the U.S. and elsewhere,
including Canada, Australia, New Zealand, Japan, Korea, Hong Kong, and even egalitarian Nordic European
countries with robust social safety nets (Denmark, Norway, Sweden, and Finland).
Preventable mortality is difficult to mitigate for a multitude of reasons, including numerous determinants at
individual, interpersonal, community, and societal levels. However, there is some cause for optimism based on
the potency of action levers at the individual level. Among SES- and race/ethnicity-related health disparities in
the U.S., 11 preventable conditions cause >50% of mortality. Further, our preliminary modeling work suggests
that only 9 prevention goals are required to attain 40% mortality reduction from these 11 conditions, resulting in
20% mortality reduction overall, because of interdependencies and common pathways. For example, alcohol
use disorder and/or heavy drinking impacts not only liver failure, but also behavioral consequences such as
sexual risk-taking and medication nonadherence.
However, attaining 20% mortality reduction would require a radical transformation of preventive care, such as
what we propose, focused on personalization, navigation, and compensation. Personalization means
maximizing individual-level benefit by modulating intensity of screening, frequency of screening; and intensity
or duration of response; navigation means reducing barriers posed by fragmentation of health and social
systems; and compensation means offsetting dependent care, time costs, and travel costs.
The post-R34-goal is a N=15,000 5-year RCT which would have adequate power to test the hypothesis of 20%
mortality reduction from personalization, navigation, and compensation. This proposed R34 is preparatory for
that goal, and focuses especially on alcohol use disorder and heavy drinking, HIV risk, and risk for
cardiovascular disease.
Public Health Relevance Statement
NARRATIVE
More people die of preventable disease in the United States than in other wealthy countries, especially among
people with lower education or incomes. Previous research shows that 9 prevention goals could prevent most
of these deaths. This proposal prepares to test whether free, convenient, and individualized training programs
targeting these 9 goals could prevent deaths.
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
121911077
UEI
M5SZJ6VHUHN8
Project Start Date
15-August-2022
Project End Date
31-July-2025
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$243,656
Direct Costs
$143,750
Indirect Costs
$99,906
Year
Funding IC
FY Total Cost by IC
2024
National Institute on Alcohol Abuse and Alcoholism
$243,656
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R34AA030484-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R34AA030484-03
Patents
No Patents information available for 5R34AA030484-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R34AA030484-03
Clinical Studies
No Clinical Studies information available for 5R34AA030484-03
News and More
Related News Releases
No news release information available for 5R34AA030484-03
History
No Historical information available for 5R34AA030484-03
Similar Projects
No Similar Projects information available for 5R34AA030484-03